博客

免疫球蛋白

Considering IVIG for Polymyositis? Here’s What You Need to Know

Woman having symptoms of polymyositis

A growing number of medical literature suggests the use of IVIG for polymyositis. IVIG may be particularly beneficial in chronic, treatment-resistant cases. 

获得 IVIG 事先授权

(877) 778-0318

Corticosteroids and immunosuppressants are the first-line treatment for polymyositis (PM). However, they may cause severe side effects. Moreover, many patients fail to improve with these treatments. 

Therefore, your doctor may consider intravenous immunoglobulin (免疫球蛋白). 

According to the EFNS guidelines for the use of intravenous immunoglobulin in the treatment of neurological diseases, “IVIG may be considered one of the treatment options for polymyositis when first-line immunosuppressive treatment fails.” [1]

Similarly, the National Blood Authority Australia recommends IVIG to treat significant muscle weakness or difficulty swallowing in [2]:

  • Adults with biopsy-proven PM unresponsive to corticosteroids and immunosuppressants. 
  • Children with definite PM unresponsive to corticosteroids and immunosuppressants. 

IVIG for Polymyositis: Navigating the Benefits From the Past to the Present

Early reports on the use of IVIG for polymyositis appeared in 1987 [3].
In the case report published in the “Journal of American Medical Association (JAMA),” investigators observed significant improvements in muscle strength and lung function in a 15-year-old girl. The girl previously received corticosteroids and immunosuppressants without substantial benefits. 

Since then, many studies have confirmed the benefits of IVIG for polymyositis resistant to conventional therapies. 

For instance, a 2008 case report found that IVIG (0.04 kg/day for 5 days) resulted in improved muscle strength [4]. The participant was resistant to previous treatment with methylprednisolone and 环磷酰胺

According to an extensive review published in 2023, IVIG appears to be a safe and effective treatment for PM that helps [5]:

  • Improve muscle strength
  • Reduce CK (creatinine kinase) levels
  • Improve swallowing difficulty

Likewise, authors of a 2023 review conclude that IVIG may be used as a first-line, steroid-sparing drug or as an add-on to conventional therapies. They also stress the need to customize IVIG therapy relevant to specific cases [6].

IVIG for Polymyositis: Mechanism of Action

The exact mechanism of action is not fully understood. 

In polymyositis, white blood cells enter into and destroy the muscle fibers. IVIG suppresses these cells and helps improve your symptoms. 

Researchers believe IVIG may also work in other ways, such as by [7]:

  • Boosting your immune system 
  • Keeping your body from making large amounts of autoantibodies (proteins that destroy muscle fibers)
  • Blocking the action of pro-inflammatory molecules 
  • Neutralizing molecules that trigger inflammation 

IVIG for Polymyositis: How Effective Is It?

Nearly 70% of participants in a 2002 clinical trial experienced improved symptoms. The improvements were sustained in about 50% of the participants in a 3-year follow-up period after stopping IVIG therapy [8].

Case reports also support the use of IVIG for polymyositis-associated lung scarring [9].
The response may vary depending on:

  • Individual patient factors
  • Stage of the disease
  • Type of IVIG product used
  • Presence/absence of associated medical conditions

获得 IVIG 共付额援助 – 与专家交谈

咨询 IVIG 专家

IVIG for Polymyositis: Understanding the Potential Barriers

Though IVIG is an effective treatment for polymyositis, accessibility to IVIG products and cost remain significant barriers. 
 

What Is the Latest Treatment for Polymyositis?

Many health experts consider IVIG alone or with immunosuppressants a more effective option for treatment-refractory polymyositis. 
 

What Are Some Associated Conditions?

Polymyositis can be associated with other conditions, such as myocarditis (inflammation of the heart’s muscular walls) or lung scarring. Moreover, polymyositis may increase the risk of cancer. 
 

What Blood Test Shows Polymyositis?

Your doctor will likely order specific blood tests if your symptoms suggest polymyositis. One of these blood tests measures the levels of an enzyme called creatinine kinase (CK). CK levels are usually high in people with polymyositis. 
 

参考:

  1. Elovaara, I et al. “EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.” European journal of neurology vol. 15,9 (2008): 893-908. doi:10.1111/j.1468-1331.2008.02246.x
  2. National Blood Authority. Inflammatory myopathies: polymyositis (PM), dermatomyositis (DM) and necrotising autoimmune myopathy (NAM) Conditions for which IVIg has an established therapeutic role. https://blood.gov.au/system/files/Inflammatory-myopathies-PM-DM-and-NAM-CV3.pdf 
  3. Roifman, C M et al. “Reversal of chronic polymyositis following intravenous immune serum globulin therapy.” JAMA vol. 258,4 (1987): 513-5. doi:10.1001/jama.1987.03400040111034
  4. Kristofova, B et al. “Successful therapy with intravenous immunoglobulin in the management of polymyositis.” Bratislavske lekarske listy vol. 109,9 (2008): 412-3.
  5. Xiong, Anji et al. “The therapeutic efficacy and safety of intravenous immunoglobulin in dermatomyositis and polymyositis: A systematic review and meta-analysis.” Modern rheumatology vol. 33,3 (2023): 533-542. doi:10.1093/mr/roac057
  6. Gandiga, Prateek C et al. “Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.” Current rheumatology reports vol. 25,8 (2023): 152-168. doi:10.1007/s11926-023-01105-w
  7. Patwardhan, Anjali. “The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics.” Cureus vol. 12,2 e7049. 19 Feb. 2020, doi:10.7759/cureus.7049
  8. Cherin, Patrick et al. “Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.” Arthritis and rheumatism vol. 46,2 (2002): 467-74. doi:10.1002/art.10053
  9. Soran Peshbahar & Elisabeth Bendstrup (2020) Remarkable benefits of intravenous immunoglobulin (IVIG) in a patient with polymyositis-associated acute interstitial lung disease, European Clinical Respiratory Journal, 7:1, 1840706, DOI: 10.1080/20018525.2020.1840706
此信息不能替代医疗建议或治疗。在开始任何新的治疗之前,请咨询您的医生或医疗保健提供者,了解您的医疗状况。AmeriPharma® Specialty Care 对所提供的信息或由此做出的任何诊断或治疗不承担任何责任,也不对其内容的可靠性负责。AmeriPharma® Specialty Care 并非运营此处列出的所有网站/组织,也不对其内容的可用性或可靠性负责。这些列表并不暗示或构成 AmeriPharma® Specialty Care 的认可、赞助或推荐。本网页可能包含对品牌处方药的引用,这些处方药是与 AmeriPharma® Specialty Care 无关的制药商的商标或注册商标。
医学审核人 Christine Leduc 博士,药学博士

Christine Leduc 博士,药学博士,在加州尔湾市出生长大。她就读于中西部大学,并以优异成绩毕业。她工作中最有成就感的部分是建议改变生活方式,教育患者了解药物的药理作用,以及指导未来的药剂师。她的专业领域是客户服务和专科药物知识。她曾在服务行业工作,积累了理解患者需求所需的客户服务技能。Leduc 博士目前正在指导马歇尔·B·凯彻姆大学、堪萨斯大学和中西部大学的学生。闲暇时,她喜欢旅行、烘焙和园艺。 参见作者简介

联系我们

使用下方符合 HIPAA 标准的表格申请续药。如果您对药物或用药方法有任何疑问,请访问“联系我们”页面或致电 (877) 778-0318.

HIPAA Compliant

提交即表示您同意 AmeriPharma 的 使用条款, 隐私政策, 和 隐私惯例通知

zh_CNChinese